Skip to main content

Table 6 Characteristics and medical costs of patients in the non-persistent group

From: Persistence rates and medical costs of biological therapies for psoriasis treatment in Japan: a real-world data study using a claims database

 

Total

BT-naïve

ADL

IFX

UST

Sub

total

ADL

IFX

UST

Subtotal

Number of patients

12

14

8

35

10

13

7

31

Average Age

46.1

47.3

50.5

47.8

47.9

48.5

51.1

49.1

%Female

8.3%

21.4%

12.5%

14.3%

10.0%

23.1%

14.3%

16.1%

Cost (pre)

¥595

¥902

¥808

¥762

¥367

¥848

¥621

¥629

In 1000

JPY unit

IP

¥0

¥231

¥32

¥108

¥0

¥249

¥36

¥122

OP

¥332

¥259

¥448

¥324

¥81

¥198

¥232

¥166

RX

¥263

¥412

¥328

¥330

¥286

¥401

¥353

¥341

Cost increase

¥1504

¥2507

¥1828

¥1937

¥1620

¥2608

¥2254

¥2126

In 1000

JPY unit

IP

¥170

¥933

¥362

¥511

¥204

¥1005

¥414

¥577

OP

¥932

¥1749

¥1638

¥1395

¥946

¥1756

¥2021

¥1499

RX

¥402

- ¥175

- ¥172

¥31

¥470

- ¥153

- ¥181

¥50

  1. ADL Adalimumab, IFX Infliximab, UST Ustekinumab, pre:12 months pre-initiation, cost increase: increase from pre to post 12 months post-initiation, JPY Japanese Yen, IP inpatient medical costs, OP outpatient medical cost, RX costs of drugs other than BTs